

## AMENDMENT OF CLAIMS

### In the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (previously presented): A composition comprising a construct, wherein the construct comprises:

- (a) a CR2 or a fragment thereof, wherein the fragment contains at least the first two N-terminal SCR domains of the CR2 protein; and
- (b) a modulator of complement activity.

Claim 2 (original): The composition of claim 1, wherein the construct is a fusion protein.

Claim 3 (canceled)

Claim 4 (previously presented): The composition of claim 1, wherein the modulator of complement activity comprises a complement inhibitor.

Claim 5 (previously presented): The composition of claim 4, wherein the complement inhibitor comprises the first four SCR domains of decay accelerating factor (DAF).

Claim 6 (previously presented): The composition of claim 4, wherein the composition comprises SEQ ID NO. 10.

Claim 7 (previously presented): The composition of claim 4, wherein the composition comprises SEQ ID NO. 6.

Claim 8 (previously presented): The composition of claim 4, wherein the complement inhibitor comprises CD59.

Claim 9 (original): The composition of claim 8, wherein the composition comprises SEQ ID NO. 12.

Claim 10 (original): The composition of claim 8, wherein the composition comprises SEQ ID NO. 8.

Claims 11-14 (canceled)

Claim 15 (previously presented): The composition of claim 4, wherein the complement inhibitor comprises Crry.

Claim 16 (original): The composition of claim 15, wherein the complement inhibitor comprises SEQ ID NO. 17.

Claim 17 (previously presented): The composition of claim 8, wherein the complement inhibitor is murine CD59 or human CD59.

Claim 18 (canceled)

Claim 19 (previously presented): The composition of claim 1, wherein the modulator of complement activity comprises a complement activator.

Claims 20-26 (canceled)

Claim 27 (previously presented): The composition of claim 19, wherein the complement activator comprises CVF.

Claim 28 (original): The composition of claim 27, wherein the complement activator comprises SEQ ID NO. 24.

Claim 29 (original): The composition of claim 1, wherein the construct is an immunoconjugate.

Claim 30 (previously presented): A method of treating a condition affected by complement in a subject comprising administering to the subject the composition of any of claims 1, 2, 4, 19, or 52.

Claim 31 (original): The method of claim 30, wherein the condition is a cancer.

Claim 32 (canceled)

Claim 33 (previously presented): The method of claim 30, wherein the condition is selected from the group consisting of a viral infection, a bacterial infection, a parasitic infection, and a fungal infection.

Claims 34-40 (canceled)

Claim 41 (original): The method of claim 30, wherein the condition is an inflammatory condition.

Claims 42-45 (canceled)

Claim 46 (previously presented): A method of reducing complement-mediated damage comprising administering to a subject the composition of any of claims 1, 2, 4, or 52.

Claim 47 (previously presented): A method of enhancing complement-mediated damage comprising administering to a subject the composition of any of claims 1, 2, 19 or 52.

Claim 48 (previously presented): The composition of claim 2, wherein the CR2 or a fragment thereof is fused to the N-terminus of the modulator of complement activity.

Claim 49 (previously presented): The composition of claim 2, wherein the CR2 or a fragment thereof is fused to the C-terminus of the modulator of complement activity.

Claim 50 (previously presented): The composition of claim 1, wherein the CR2 or a fragment thereof comprises a full-length CR2 protein.

Claim 51 (previously presented): The composition of claim 1, wherein the CR2 or a fragment thereof comprises the four N-terminal SCR domains of the CR2 protein.

Claim 52 (previously presented): The composition of claim 1, wherein the modulator of complement activity is selected from the group consisting of Crry, CD59, DAF, CVF, and a fragment thereof.

Claim 53 (previously presented): The composition of claim 4, wherein the complement inhibitor comprises the first five N-terminal SCR domains of Crry.

Claim 54 (previously presented): The composition of claim 4, wherein the complement inhibitor comprises the extracellular region of CD59.

Claim 55 (previously presented): A method of targeting a modulator of complement activity to a site of complement activation in a subject by administering to the subject a composition of any of claims 1, 2, 4, 8, 17, 19 or 52.

Claim 56 (previously presented): A method of treating an inflammatory condition in a subject by administering to the subject a composition of any of claims 1, 2, 4, 8, 17 or 52.

Claim 57 (previously presented): The method of claim 56, wherein the inflammatory condition is stroke.

Claim 58 (previously presented): The method of claim 56, wherein the inflammatory condition is ischemia reperfusion injury.

Claim 59 (previously presented): A nucleotide sequence encoding a fusion protein of claim 2.

Claims 60-73 (canceled)

Claim 74 (new): The composition of claim 19, wherein the complement activator is an immunoglobulin.

Claim 75 (new): The composition of claim 74, wherein the immunoglobulin is IgG1 Fc.

Claim 76 (new): The composition of claim 74, wherein the immunoglobulin is IgM Fc.

Claim 77 (new): The composition of claim 74, wherein the immunoglobulin is IgG3 Fc.

Claim 78 (new): The method of claim 30, comprising administering to the subject the composition of claim 19 comprising a complement activator.

Claim 79 (new): The method of claim 78, wherein the complement activator is an immunoglobulin.

Claim 80 (new): The method of claim 79, wherein the immunoglobulin is an IgG1 Fc.

Claim 81 (new): The method of claim 79, wherein the immunoglobulin is an IgM Fc.

Claim 82 (new): The method of claim 79, wherein the immunoglobulin is an IgG3 Fc.